Eli Lilly Zepbound Performance - Search News

News

Zepbound beats Wegovy for weight loss

EconoTimes · 2d

Eli Lilly’s Zepbound Outperforms Wegovy in Weight Loss Head-to-Head Trial

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key weight-loss metrics, including waist circumference reduction. Results from the

Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week head-to-head trial.

Investor's Business Daily on MSN · 12d

Eli Lilly Slumps 5% On Profit Guidance Cut Despite Mounjaro, Zepbound Beats

Eli Lilly stock fell Thursday after the drugmaker cut its full-year profit guidance despite a first-quarter beat.

1h

1LLY : Unpacking the Latest Options Trading Trends in Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

12d

CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Zacks.com on MSN4h

Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

13don MSN

Eli Lilly’s Shares Sink on Investor Concerns About CVS Move

Eli Lilly & Co.’s shares dropped in morning trading after CVS Health Corp. announced a plan to drop its blockbuster ...

13don MSN

Why Eli Lilly Stock Is Sinking Today

Shares of Eli Lilly ( LLY -5.50%) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m. ET. The leg down comes as the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results